Target : Actualité Target en direct - P1 | Bourse Reflex
Accueil > Tags > Target

  • Toutes les actualités en rapport avec « Target »

02/05 07:30 Target - ORAL PRESENTATION OF THERANEXUS AT THE 9TH EUROPEAN CONGRESS ON NARCOLEPSY 5 AND 6 MAY IN MONTPELLIER

27/04 07:00 Target - Strong revenue growth for Prodways Group in Q1 2018 (up 81%)

27/04 07:00 Target - ECA Group: first quarter 2018 revenue of 22.8 million euros; good order intake

26/04 18:00 Target - 2017/18 annual revenue grows by 6% - EBIT margin expected to exceed target

26/04 18:00 Target - THERANEXUS ANNOUNCES ITS 2017 ANNUAL RESULTS AND PRESENTS AN UPDATE ON THE PROGRESS OF ITS CLINICAL TRIALS

26/04 17:45 Target - SES-imagotag: Q1 2018 Sales

23/04 19:45 Target - 2017 YEARLY RESULTS

23/04 07:30 Target - THN102 OBTAINS INVESTIGATIONAL NEW DRUG STATUS FROM THE FOOD AND DRUG ADMINISTRATION (FDA)

23/04 07:00 Target - ABEO successfully completes its first bond issue (Euro PP) for EUR 20m

19/04 18:00 Target - THERANEXUS ANNOUNCES THE FIRST EUROPEAN APPROVAL FOR ITS PHASE 2 CLINICAL TRIAL WITH THN 102 IN PARKINSON'S DISEASE PATIENTS

19/04 17:45 Target - Quantum Genomics enters a new phase of maturity with its BAPAIs Fast Growth strategic plan

03/04 07:00 Target - Prodways Group: strong growth and clear results improvement in 2017

29/03 18:00 Target - Quantum Genomics publishes its financial results for the year 2017

29/03 11:00 Target - 2017 RESULTS: STRONG REVENUE GROWTH, PROFIT GENERATED IN SECOND HALF NEW STRATEGIC PLAN AND PLANNED SHARE ISSUE

28/03 18:00 Target - FULL YEAR 2017 RESULTS

21/03 09:00 Target - STRONG PERFORMANCE IN 2017 : TURNOVER UP 45% - EBITDA MARGIN OVER 25%

21/03 07:30 Target - THERANEXUS ANNOUNCES A SUCCESSFUL CLINICAL PHARMACOKINETIC STUDY AS PART OF THE DEVELOPMENT OF ITS DRUG CANDIDATES THN201 AND THN101

15/03 07:30 Target - THERANEXUS AND THE COLLEGE DE FRANCE SIGN A RESEARCH AGREEMENT ON ASTROCYTE-NEURON INTERACTIONS

14/03 17:45 Target - 2017 full-year results : Revenues up 8.3% - Recurring operating margin up 9.6 % - Net income Group share up 12.5% to EUR 23.9 million

05/03 18:30 Target - Quantum Genomics Secures Operational Flexibility and Growth Capital through Equity Line Financing with Kepler Cheuvreux